Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The NHS spending watchdog has recommended brentuximab vedotin, sold under the brand name Adcetris, to be used in combination ...

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide and a rituximab product for the treatment of ...

The Japanese pharma has been building a presence in oncology over the last few years through products such as its Adcetris (brentuximab vedotin), and its $5.2 billion acquisition of Ariad at the ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.